Focused On-demand Library for CMP-N-acetylneuraminate-beta-1,4-galactoside alpha-2,3-sialyltransferase

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:

Beta-galactoside alpha-2,3-sialyltransferase 3; Gal beta-1,3(4) GlcNAc alpha-2,3 sialyltransferase; N-acetyllactosaminide alpha-2,3-sialyltransferase; ST3Gal III; ST3N; Sialyltransferase 6

Alternative UPACC:

Q11203; A9Z1W2; D3DPX8; Q5T4W9; Q5T4X0; Q5T4X7; Q5T4X8; Q5T4X9; Q5T4Y0; Q5T4Y2; Q5T4Y3; Q5T4Y4; Q86UR6; Q86UR7; Q86UR8; Q86UR9; Q86US0; Q86US1; Q86US2; Q8IX41; Q8IX42; Q8IX43; Q8IX44; Q8IX45; Q8IX46; Q8IX47; Q8IX48; Q8IX49; Q8IX50; Q8IX51; Q8IX52; Q8IX53; Q8IX54; Q8IX55; Q8IX56; Q8IX57; Q8IX58


CMP-N-acetylneuraminate-beta-1,4-galactoside alpha-2,3-sialyltransferase, also known as ST3Gal III, plays a crucial role in the biosynthesis of sialylated glycoproteins and glycolipids. This enzyme catalyzes the addition of sialic acid to terminal carbohydrate groups, a process vital for cell-cell communication and pathogen recognition.

Therapeutic significance:

The enzyme's association with Intellectual developmental disorder, autosomal recessive 12, and Developmental and epileptic encephalopathy 15, underscores its potential as a target for therapeutic intervention. Understanding ST3Gal III's role could pave the way for novel treatments for these neurological disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.